Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Lilly GMPs Clear One Milestone; Cymbalta Launch Now Planned For Summer

  • News

Executive Summary

Lilly plans to launch Cymbalta in summer 2004, pending a pre-approval inspection and the build-up of sufficient product inventory

You may also be interested in...



Lilly Cymbalta Launched At Premium Price; Once-Daily Dose Encouraged

Lilly's antidepressant Cymbalta is priced at a 73% premium to Wyeth's Effexor XR

Lilly Cymbalta Launched At Premium Price; Once-Daily Dose Encouraged

Lilly's antidepressant Cymbalta is priced at a 73% premium to Wyeth's Effexor XR

Cymbalta Superior To SSRIs, Lilly Says; Once-Daily Dosing Not Vital To Uptake

Lilly's pending SNRI Cymbalta induces remission from depression more often than selective serotonin reuptake inhibitors, Exec VP-Science & Technology Steven Paul, MD, said

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS042746

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By